Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13741323 | 0.79 | MAPKAPK2 (0.34) | MAPKAPK2LMNAGRM5 | |
| SCHEMBL15211469 | 0.78 | ALDH1A1 (0.42) | KDM4EALDH1A1DPP4LMNA | |
| Hydrochloric Acid SCHEMBL4090437 | 0.78 | MAPKAPK2 (0.33) | MAPKAPK2LMNA | |
| SCHEMBL11328853 | 0.75 | ALDH1A1 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL30784909 | 0.74 | KDM4E (0.47) | KDM4EALDH1A1MAPKAPK2LMNA | |
| SCHEMBL21193052 | 0.74 | KDM4E (0.47) | KDM4EALDH1A1MAPKAPK2LMNA | |
| SCHEMBL12648083 | 0.72 | — | — | |
| SCHEMBL30716708 | 0.72 | — | — | |
| SCHEMBL2178063 | 0.71 | — | — | |
| SCHEMBL30828998 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2005095391-A1 | THIAZOLIUMS AS TRANSKETOLASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209554-A1 | Thiazoliums as transketolase inhibitors | TKT, RRM2, TYMS | KDM4E 299/4885ALDH1A1 766/4885MAPKAPK2 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.